Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06280482
PHASE1

Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

Sponsor: The University of Texas Health Science Center, Houston

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients.

Key Details

Gender

All

Age Range

1 Year - Any

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2024-03-06

Completion Date

2027-07-25

Last Updated

2025-09-12

Healthy Volunteers

No

Interventions

DRUG

Nicotinamide riboside (NR)

Participants will take their weight-based dose of NR once daily by mouth with food for 60 days.

Locations (1)

The University of Texas Health Science Center at Houston

Houston, Texas, United States